Novel devices: optimising drug delivery in multiple myeloma

Henry Fong, Patricia Cubi-Molla and Martina Garau

Contract Research from Office of Health Economics

Abstract: Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The notable shift from cytotoxic agents to targeted therapies has enabled subcutaneous (SC) administration as a practical alternative to intravenous (IV) infusion. There is also growing emphasis on improving patient experience, optimising healthcare workflows, and realising the full clinical and economic value of medicines—trends that favour more convenient and flexible delivery methods. This is particularly relevant in multiple myeloma where patients often undergo extended treatment courses and biologics provide substantial improvements in survival outcomes. The…

JEL-codes: I1 (search for similar items in EconPapers)
Date: 2025-12-09
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/novel-devices-opt ... in-multiple-myeloma/ (text/html)
https://www.ohe.org/wp-content/uploads/2025/12/Fon ... multiple-myeloma.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:conres:002527

Access Statistics for this paper

More papers in Contract Research from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).